BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares
Results from a phase 2b trial are"clearly encouraging" and"support the hypothesis that BAFF [B-cell-activating factor] can drive flares after rituximab," said Michael Ehrenstein, MD.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 4, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

Experimental Treatment Offers New Hope Against Lupus
Title: Experimental Treatment Offers New Hope Against LupusCategory: Health NewsCreated: 5/27/2021 12:00:00 AMLast Editorial Review: 5/28/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 28, 2021 Category: Rheumatology Source Type: news

Rheumatoid arthritis and systemic lupus erythematosus during COVID-19 quarantine period
This study aimed to investigate self-reported symptoms of disease flares among patients with rheumatoid arthritis or systemic lupus erythematosus during the COVID-19 pandemic. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news

Experimental Treatment Offers New Hope Against Lupus
A small, early "phase 1" trial finds an experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus. (Source: WebMD Health)
Source: WebMD Health - May 27, 2021 Category: Consumer Health News Source Type: news

Experimental Treatment Offers New Hope Against Lupus
THURSDAY, May 27, 2021 -- An experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus, a small preliminary trial suggests. Researchers found that a higher-dose version of the drug spurred a " clinically meaningful " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 27, 2021 Category: General Medicine Source Type: news

Biotech firm Asylia Therapeutics raises $14.5M, names founding CEO
Houston-based biotechnology firm Asylia Therapeutics Inc. raised $14.5 million to advance its clinical trials for cancer drugs. The Series A round was led by Houston-based Sporos Bioventures, Asylia announced May 25. The company will use proceeds to bring Asylia's assets to first-in-human clinical trials for oncology. Asylia could potentially generate proof-of-concept signals for its clinical assets in treating autoimmune diseases like lupus, the firm said. "While cancer research has come a significant… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 25, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news

Rogue antibodies wreak havoc in severe COVID-19 cases
The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in severe cases of COVID-19, Yale scientists report in the journal Nature. These autoantibodies target and react with a person's tissues or organs similar to ones that cause autoimmune diseases such as lupus or rheumatoid arthritis. (Source: World Pharma News)
Source: World Pharma News - May 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

How Is Lupus Nephritis Treated
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 12, 2021 Category: General Medicine Source Type: news

Vaccination Rates Low Among Lupus Patients on Medicaid
TUESDAY, May 11, 2021 -- Medicaid beneficiaries with systemic lupus erythematosus (SLE) who are not vaccinated are at risk for potentially avoidable acute care use for vaccine-preventable illnesses, according to a study published online May 4 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2021 Category: Pharmaceuticals Source Type: news

What Are The Six Classes of Lupus Nephritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 7, 2021 Category: General Medicine Source Type: news

Arthritis: The best type of diet to ease inflammation in the body – what to eat
ARTHRITIS caused by misdirected inflammation include rheumatoid, psoriatic, systemic lupus erythematosus, gout and ankylosing spondylitis. Could an anti-inflammatory diet help ease symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - May 6, 2021 Category: Consumer Health News Source Type: news

Study uncovers potentially avoidable acute care use for vaccine-preventable illnesses in lupus patients
(Wiley) A new study published in Arthritis Care& Research indicates that few individuals with the autoimmune disease lupus who were publicly insured through Medicaid received recommended vaccines in 2000-2010. Also, those who were unvaccinated needed more acute care for vaccine-preventable illnesses. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2021 Category: International Medicine & Public Health Source Type: news

Rituximab Benefits Seen in Neuropsychiatric Lupus Rituximab Benefits Seen in Neuropsychiatric Lupus
Additionally, the use of concomitant cyclophosphamide might enhance the level of improvement seen in some patients, said Dr Trixy David in presenting data at the British Society for Rheumatology meeting.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

B Cells in Relapsing Lupus Nephritis and Cutaneous Vasculitis B Cells in Relapsing Lupus Nephritis and Cutaneous Vasculitis
A case of a woman with systemic lupus erythematosus whose nephritis and cutaneous vasculitis were refractory to treatment.HSS Grand Rounds Complex Cases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2021 Category: Consumer Health News Tags: Rheumatology Clinical Case Source Type: news

Physical activity reduces cardiovascular risk in rheumatic patients
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) People with diseases such as rheumatoid arthritis and lupus are more likely to have heart attacks, angina, and strokes. A review of the scientific literature on the subject shows that regular exercise improves vascular function in these patients (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2021 Category: International Medicine & Public Health Source Type: news

Patient Benefits Justify Price of New Lupus Nephritis Drugs Patient Benefits Justify Price of New Lupus Nephritis Drugs
Prices of two new drugs approved by the FDA for lupus nephritis are in reasonable alignment with their estimated benefits for patients with the disease, a report indicates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule... (Source: The Scientist)
Source: The Scientist - April 22, 2021 Category: Science Tags: The Scientist The Marketplace Source Type: news

Quinacrine: Au Revoir or Adieu? Quinacrine: Au Revoir or Adieu?
Quinacrine is a safe and effective antimalarial agent. Does it have a place in the treatment of lupus?Current Opinion in Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Renal, CV Damage May Develop in Mild SLE Despite Treatment Renal, CV Damage May Develop in Mild SLE Despite Treatment
An increase in disease activity in systemic lupus erythematosus is associated with significant increases in the risk of renal and cardiovascular damage.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

Masonic Medical Research Institute awarded Department of Defense Lupus Impact Award
(Masonic Medical Research Institute) Lupus is a common and devastating autoimmune disease that has no cure and current treatments only work to improve symptoms, which often have secondary, even devastating, side effects. Therefore, there is significant need and urgency to identify more specific and targeted therapies for this disease. Dr. Maria Kontaridis, Executive Director at MMRI aims to try to do just this, with grant support from a newly garnered Department of Defense (DOD) Lupus Impact Award, totaling $750,000. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2021 Category: International Medicine & Public Health Source Type: news

Helping childhood-onset lupus patients stay healthy as adults
(UT Southwestern Medical Center) DALLAS - March 30, 2021 - UT Southwestern researchers have identified factors that put patients with childhood-onset lupus at elevated risk for poor outcomes, such as end-stage renal disease or death, as they transition from pediatric to adult health care. The findings, published online in Seminars in Arthritis and Rheumatism, emphasize the precarious nature of this period and shine a spotlight on areas prime for intervention to help protect these vulnerable patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2021 Category: International Medicine & Public Health Source Type: news

Vitamin D deficiency linked to metabolic changes in patients with lupus - study
(University of Birmingham) Patients with lupus are more likely to have metabolic syndrome and insulin resistance - both factors linked to heart disease - if they have lower vitamin D levels, a new study reveals. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2021 Category: International Medicine & Public Health Source Type: news

Research group identifies potential therapeutic target for lupus
(Michigan Medicine - University of Michigan) Inhibiting IRE1α, a molecule activated by the endoplasmic reticulum in neutrophils, counters disease progression in lupus mice. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2021 Category: International Medicine & Public Health Source Type: news

COVID-19's Impact on Lupus Inpatients Examined in Study COVID-19's Impact on Lupus Inpatients Examined in Study
' Recently, anti-interferon antibodies have been implicated in severe SARS-CoV-2 infection while it has been known for decades that patients with SLE may produce such autoantibodies. 'Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - March 25, 2021 Category: Infectious Diseases Tags: Rheumatology News Source Type: news

Lupus Research Alliance announces awards aimed at new lupus treatments
(Lupus Research Alliance) The Lupus Research Alliance proudly announces two exceptional recipients of the 2020 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Jacques Banchereau, PhD and Ignacio Sanz, MD. Both projects funded by this grant are investigating different mechanisms altered in lupus patients that induce an autoimmune response. Their findings could lead to the development of more precise treatments to prevent lupus onset or progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Yes or No: The Future of Rheumatology Is Sub-Subspecialization Yes or No: The Future of Rheumatology Is Sub-Subspecialization
It makes little sense for some rheumatologists to declare they're only going to see patients with psoriatic arthritis, or gout, or lupus.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

January-February 2021 RefSeq annotations include dog, fly, rat
This January and February, the NCBI Eukaryotic Genome Annotation Pipeline released new annotations in RefSeq for the following organisms: Benincasa hispida (wax gourd) Canis lupus familiaris (dog) Corvus cornix cornix (hooded crow) Crotalus tigris (tiger rattlesnake) Culex pipiens pallens (northern house mosquito) Dioscorea cayenensis subsp. rotundata (Guinea yam) Drosophila santomea (fly) Drosophila simulans (fly) Drosophila … Continue reading January-February 2021 RefSeq annotations include dog, fly, rat → (Source: NCBI Insights)
Source: NCBI Insights - March 16, 2021 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New Eukaryotic genome annotation RefSeq Source Type: news

Nearly 20% of Lupus Patients Have Severe Infection in First Decade After Diagnosis Nearly 20% of Lupus Patients Have Severe Infection in First Decade After Diagnosis
Infections remain a leading cause of morbidity and early mortality in patients with SLE, writes Kai Zhao, MSc, of Arthritis Research Canada, Richmond, and colleagues.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - March 12, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Lipid presentation by the protein C receptor links coagulation with autoimmunity
Antiphospholipid antibodies (aPLs) cause severe autoimmune disease characterized by vascular pathologies and pregnancy complications. Here, we identify endosomal lysobisphosphatidic acid (LBPA) presented by the CD1d-like endothelial protein C receptor (EPCR) as a pathogenic cell surface antigen recognized by aPLs for induction of thrombosis and endosomal inflammatory signaling. The engagement of aPLs with EPCR-LBPA expressed on innate immune cells sustains interferon- and toll-like receptor 7–dependent B1a cell expansion and autoantibody production. Specific pharmacological interruption of EPCR-LBPA signaling attenua...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Müller-Calleja, N., Hollerbach, A., Royce, J., Ritter, S., Pedrosa, D., Madhusudhan, T., Teifel, S., Meineck, M., Häuser, F., Canisius, A., Nguyen, T. S., Braun, J., Bruns, K., Etzold, A., Zechner, U., Strand, S., Radsak, M., Strand, D., G Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news

Cochrane Library Editorial - Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19
During the past 12 months chloroquine and hydroxychloroquine have been touted as cures for COVID-19 and introduced into Covid-19 treatment protocols. This has led to increases in demand, leaving some rheumatoid arthritis and lupus patients deprived of effective treatments.A newly publishedCochrane Library Editorial explores the story of the assessment of  chloroquine and hydroxychloroquine efficacy and the lessons learnt. This Editorial publishes alongside the  recently published review published in the Cochrane Library   that concludes that hydroxychloroquine   has no clinical benefit in...
Source: Cochrane News and Events - March 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

JDRF, Lupus Research Alliance and National Multiple Sclerosis Society join forces to decode common m
(JDRF) JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are proud to announce the recipients of their first joint grants. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 24, 2021 Category: International Medicine & Public Health Source Type: news

Lupus More Deadly for Asian and Hispanic Americans: Study
TUESDAY, Feb. 23, 2021 -- More Asian and Hispanic people with lupus die prematurely than white patients, a new study reveals. Death rates in San Francisco were nearly six times higher than expected among Hispanic patients with lupus and four times... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 23, 2021 Category: General Medicine Source Type: news

Mortality Highest  for Asians, Hispanic/Latinos With Lupus
FRIDAY, Feb. 19, 2021 -- Standardized mortality ratios (SMRs) of observed-to-expected deaths are increased for patients with systemic lupus erythematosus (SLE) and are especially high for Asians and Hispanic/Latinos, according to research published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons - California, 2007-2017
This report describes mortality among minority populations with systemic lupus erythematosus. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - February 18, 2021 Category: American Health Tags: Asian American & Pacific Islander Health Hispanic health Lupus (Systemic lupus erythematosus) Minority Health MMWR Morbidity Mortality Weekly Report Mortality Data Latino Health Source Type: news

Covid-19 Vaccines And Autoimmune Disease
What are recommendations for Covid-19 vaccinations in patients with autoimmune diseases like lupus or rheumatoid arthritis? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 17, 2021 Category: Pharmaceuticals Authors: Judy Stone, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Platelets may play key role in development of lupus
(Universit é Laval) Platelets may play a key role in the development of lupus, according to a study published today by researchers at Universit é Laval and CHU de Qu é bec-Universit é Laval Research Centre. Extracellular DNA circulating in the blood of patients with lupus causes the inflammatory reaction associated with the disease. The researchers have shown that this DNA comes in part from the platelets, better known for their role in coagulating blood. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2021 Category: International Medicine & Public Health Source Type: news

Starting from the beginning may lead to better outcomes for lupus
Lupus is a chronic autoimmune disorder that causes inflammation and pain throughout the body. Most common in women (9 of 10 diagnosed cases); it attacks both joints and organs - including the skin. Lupus is not curable, but symptoms can be managed with medications. Researchers hope to learn more about lupus and identify ways to predict [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - February 16, 2021 Category: Research Source Type: news

Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
COVID-19 is an infectious respiratory disease caused by a coronavirus called SARS-CoV-2. If the infection becomes severe, people may need intensive care and support in hospital, including mechanical ventilation.Drugs used for other diseases were tried out in COVID-19, and this included chloroquine, used for malaria; and hydroxychloroquine used for rheumatic diseases, such as rheumatoid arthritis or systemic lupus erythematosus. The authors sought evidence of the effects of these drugs in treating people ill with the disease; in preventing the disease in people at risk of getting the disease, such as health workers; and peo...
Source: Cochrane News and Events - February 10, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing. Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Meta-Analysis Finds Much Less Lupus Than Expected Meta-Analysis Finds Much Less Lupus Than Expected
The prevalence of systemic lupus erythematosus appears to be much lower than previously believed and may pose'a potential risk to research funding for the disease. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA Approves Voclosporin for Lupus Nephritis FDA Approves Voclosporin for Lupus Nephritis
Lupkynis is a calcineurin-inhibitor immunosuppressant, and is the first oral medication to show effectiveness in lupus nephritis, according to the company.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 27, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis
VICTORIA, British Columbia& ROCKVILLE, Md.-- January 22, 2021 -- Aurinia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin) in combination with a background... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 22, 2021 Category: Drugs & Pharmacology Source Type: news

More Than 200,000 Americans Have Lupus
A new study reveals how widespread the disease is in the United States. (Source: WebMD Health)
Source: WebMD Health - January 22, 2021 Category: Consumer Health News Source Type: news

Study Reveals New Insights into the Link Between Sunlight Exposure and Kidney Damage in Lupus
A new collaborative study from researchers at the Geisel School of Medicine at Dartmouth and the University of Washington and published in the Proceedings of the National Academy of Sciences (PNAS), reveals unexpected insights into how skin exposure to ultraviolet light can worsen clinical symptoms in autoimmune diseases such as lupus. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - January 21, 2021 Category: Hospital Management Authors: Timothy Dean Tags: News Research kidney lupus ultraviolet light Source Type: news

Study Estimates Prevalence of Lupus in the U.S.
THURSDAY, Jan. 21, 2021 -- The estimated prevalence of systemic lupus erythematosus (SLE) in the United States is 72.8/100,000, according to a study published online Jan. 21 in Arthritis& Rheumatology. Peter M. Izmirly, M.D., from the New York... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2021 Category: Pharmaceuticals Source Type: news

More Than 200,000 Americans Have Lupus
THURSDAY, Jan. 21, 2021 -- Just over 200,000 Americans have the autoimmune disorder lupus, and minority women are at highest risk, according to a new study. It's the first estimate of how widespread the disease is in the United States. The number... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 21, 2021 Category: General Medicine Source Type: news

More Than 200,000 Americans Have Lupus
Title: More Than 200,000 Americans Have LupusCategory: Health NewsCreated: 1/21/2021 12:00:00 AMLast Editorial Review: 1/21/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - January 21, 2021 Category: Rheumatology Source Type: news

Study finds especially high rates of lupus in certain racial/ethnic groups
(Wiley) The US prevalence of the autoimmune disease lupus is 72.8 cases per 100,000 individuals, according to an analysis of population-based registries. The analysis, which is published in Arthritis& Rheumatology, found that the rate is 9 times higher for females than males (128.7 vs. 14.6 per 100,000), and it's highest among American Indians/Alaska Natives and Black females. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news